Publication

The predictive value of immunohistochemical markers in untreated Wilms' tumour: are they useful?

Ghanem, M. A., van der Kwast, T. H., Molenaar, W. M., Safan, M. A., Nijman, R. J. & van Steenbrugge, G. J., Aug-2013, In : World journal of urology. 31, 4, p. 811-816 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • Mazen A. Ghanem
  • Theo H. van der Kwast
  • W. M. Molenaar
  • Manal A. Safan
  • Rien J. Nijman
  • Gert Jan van Steenbrugge

This study reevaluates the potential role of different tumour markers as prognostic indicators in untreated nephroblastoma.

Expression of a broad panel of tumour markers was investigated by means of immunohistochemical analysis in 43 WT patients. Patients were treated by radical nephrectomy and had a mean follow-up of 11.9 years.

Generally, all the tumour markers studied were expressed in normal kidney tissue and at variable levels in the three cell types of WT (blastema, epithelium and stroma). Immunoreactive blastemal (Bcl-X, Bcl-2 and CD44s) and epithelial (Bcl-X, Bcl-2 and MIB-1) cells were present in the majority of tumours. No correlation was found between their expression and pathological stages. Univariate analysis showed that blastemal WT-1, TGF-alpha, VEGF, MIB-1 and p27 Kip1 were indicative for clinical progression. In a multivariate analysis, WT-1 protein expression by blastemal cells was an independent prognostic marker for clinical progression.

The blastemal WT-1, TGF-alpha, VEGF, MIB-1 and p27Kip1 expression correlate with clinical progression in untreated nephroblastoma. Therefore, their expression may be of value in identifying patients with a high propensity to develop distant metastases.

Original languageEnglish
Pages (from-to)811-816
Number of pages6
JournalWorld journal of urology
Volume31
Issue number4
Publication statusPublished - Aug-2013

    Keywords

  • Wilms' tumour, Immunohistochemsitry, Untreated, Tumour markers, Prognosis, ENDOTHELIAL GROWTH-FACTOR, PAEDIATRIC-ONCOLOGY SIOP, PROGNOSTIC VALUE, CLINICAL-TRIAL, BCL-X, EXPRESSION, NEPHROBLASTOMA, PROTEINS, PROLIFERATION, MANAGEMENT

ID: 5928746